BOSTON, Oct. 13, 2020 /PRNewswire/ — Admetsys Corporation, a biomedical technology company specializing in critical care automation, announced today that it received European regulatory approval (CE Mark) for its flagship PrecisionOne™ automated glycemic control and continuous diagnostics system.
The PrecisionOne system functions as a metabolic autopilot, providing automated glucose regulation and real-time analysis of blood chemistry values for critical care patients. The majority of these patients experience hyperglycemia and metabolic instability caused by their acute condition and exacerbated by preexisting conditions such as diabetes. This increases mortality, morbidity, length of stay, and cost of care. To date, no automated glucose regulation tools have been available in the hospital.
COVID-19 dramatically illuminates the clinical need addressed by the PrecisionOne system. Among hospitalized COVID patients, hyperglycemia increases mortality 4-fold in diabetic populations and 7-fold in non-diabetic populations. Moreover, because the current standard of care requires close-contact workflow, efforts to better regulate patient glucose levels expose medical professionals to additional contagion and infection risk.